Skip to content
2000
Volume 1, Issue 3
  • ISSN: 1570-1603
  • E-ISSN: 1570-1603

Abstract

Recent sweeping advances in technology have driven a transformation in the science of pharmacogenetics. Understanding this transformation informs the future direction of the field. Generation of high density SNP and LD maps following quickly on the heels of sequencing of the human genome combining with great advances in bioinformatics have opened the door for application of candidate gene and genome-wide approaches to understanding both drug efficacy and adverse events at the DNA level. A future in which pharmacogenetics will play a critical role in drug development and clinical practice requires that we meet today's challenges. These challenges include establishing fluent dialog between pharmaceutical companies and regulatory agencies, achieving meaningful standardization of technical aspects of these new methodologies, bringing precision to the language of pharmacogenetics to provide clarity for public policy debates and realizing education goals to bring the knowledge and power of pharmacogenetic analyses to clinical practice.

Loading

Article metrics loading...

/content/journals/cpg/10.2174/1570160033476232
2003-09-01
2026-01-11
Loading full text...

Full text loading...

/content/journals/cpg/10.2174/1570160033476232
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test